NCT00104429

GW873140 In Combination With Combivir In HIV Infected Subjects

A PhaseIIb, 96 Week, Randomised, Partially Double-blinded, Multicentre, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of GW873140 in Combination With COMBIVIR (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (planned)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.

Detailed description

A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with Combivir (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults

Conditions

• Infection, Human Immunodeficiency Virus I
• HIV Infection

Interventions

Type	Name	Description
DRUG	GW873140
DRUG	Combivir

Timeline

• Start date: 2005-01-01
• Primary completion: 2006-01-01
• Completion: 2006-01-01
• First posted: 2005-03-01
• Last updated: 2017-05-30

Locations

51 sites across 9 countries: United States, Belgium, Canada, France, Germany, Italy, Portugal, Spain, United Kingdom